Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19

Detalles Bibliográficos
Autores principales: Li, Hailan, Liu, Huaping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Academy of Allergy, Asthma & Immunology 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498226/
https://www.ncbi.nlm.nih.gov/pubmed/32980157
http://dx.doi.org/10.1016/j.jaci.2020.09.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498226/
https://www.ncbi.nlm.nih.gov/pubmed/32980157
http://dx.doi.org/10.1016/j.jaci.2020.09.002

Ejemplares similares